There is no single MWA leader across every meaningful category.
Canyon has the strongest identifiable device-specific thyroid evidence. ECO appears to lead the broader Chinese MWA market in the cited 2022 data. Baird leads the cited thyroid-focused commercial segment in China. Vison is a major manufacturer that has received too little attention in thyroid-ablation analysis.
Clinical evidence
Canyon Medical, based on its randomized multicenter comparison with STARMED RFA and broader named-device thyroid literature.
Commercial scale
ECO Medical, based on the overall Chinese MWA market ranking cited in public securities filings.
Thyroid market focus
Baird Medical, based on its cited thyroid-nodule segment position and concentrated thyroid commercialization strategy.
Underrecognized scale
Vison Medical, which ranked second overall in the cited China data and has emerging large-nodule evidence.
Who leads—and by which measure?
Canyon Medical
Canyon’s strongest claim is the quality of the thyroid-specific evidence associated with its legacy KY-2000 platform—not the size of its marketing presence.
The most important study is a prospective, randomized, open-label, five-center trial comparing Canyon MWA with STARMED RFA in 152 patients with predominantly solid benign thyroid nodules. At two years, MWA was noninferior to RFA for volume reduction. Technique efficacy was reported as 91% for MWA and 86% for RFA.1
The trial also requires caution. All operators had more than ten years of thermal-ablation experience. Voice change occurred in 6.6% of MWA patients and 1.3% of RFA patients; all recovered within three months, but the study was not large enough to establish equivalent safety. The trial was supported by Canyon and public research grants.1
Canyon’s named systems also appear across substantial benign-nodule and thyroid-cancer literature, including large cohorts and long-term follow-up.2 The current MaxBlate line includes KY-2000A and KY-2100A generators and ThyTip antennas, but physicians should distinguish current configurations from the legacy KY-2000 equipment used in much of the literature.3
The current Canyon generators received U.S. FDA clearance in 2024 for general soft-tissue microwave ablation—not an explicit benign-thyroid-nodule indication.4
Why Canyon leads on evidence
- Randomized multicenter head-to-head study
- Named-device benign and cancer literature
- Longer identifiable thyroid research history
- Fine thyroid-oriented antennas
What remains unresolved
- Safety equivalence for new operators
- Continuity between legacy and current systems
- Current global installed base
- Thyroid-specific U.S. indication
ECO Medical
ECO appears to be the most commercially established of the major Chinese MWA manufacturers in the available market data.
Frost & Sullivan data cited in Baird’s securities filing ranked ECO first in China’s overall MWA market by 2022 sales revenue, followed by Vison, Baird and Canyon. The data are historical, China-specific and company-commissioned, but they confirm that ECO is a major platform rather than a peripheral supplier.5
ECO also has meaningful named-device thyroid evidence. A study of 208 predominantly solid benign nodules compared STARMED RFA with an ECO MWA generator and ECO1007 antenna. Overall 12-month outcomes were comparable; MWA required less treatment time and energy. In nodules at least 3.5 cm, MWA achieved a higher 12-month volume-reduction rate in that cohort.6
Strengths
- Established manufacturing scale
- Broad international activity
- Named-device comparative evidence
- Potential efficiency in larger nodules
Limitations
- Global thyroid volumes are not public
- Training quality varies by distributor
- Product naming can be difficult to track
- No universal evidence of superiority
Baird Medical
Baird has built the clearest thyroid-specific commercial identity among the major Chinese MWA manufacturers.
Baird’s public reporting states that the company ranked first in China in the thyroid-nodule and breast-lump segment by 2022 sales revenue and microwave-needle volume. In the same cited data, Baird ranked third in the overall Chinese MWA market, behind ECO and Vison.5
The BD-GT system received U.S. FDA 510(k) clearance in November 2023 for general soft-tissue microwave ablation. The clearance is not an explicit benign-thyroid-nodule indication.7
Baird’s strengths are concentrated thyroid branding, fine-gauge probes, expanding physician education and aggressive international distribution. Its principal limitation is that international marketing visibility currently exceeds the volume of independently visible, device-specific comparative thyroid evidence.
Strengths
- Clear thyroid-specific commercial strategy
- Strong cited China thyroid segment
- Fine thyroid-oriented probes
- Active international expansion
Limitations
- Less independent comparative evidence
- General soft-tissue U.S. clearance
- Leadership data are historical and China-specific
- Training visibility is not outcome evidence
Vison Medical
Vison is the manufacturer most likely to be overlooked in Western thyroid-ablation discussions.
Vison ranked second in China’s overall MWA market in the 2022 market research cited by Baird—above both Baird and Canyon.5 A recent retrospective study of 205 patients with benign nodules measuring at least 4 cm used Vison’s MTC-3C system and reported a mean volume-reduction rate of 82.54% and technical efficacy of 93.66%. One patient developed transient hoarseness that resolved within one month.8
Vison also designed the SurBlate system, cleared in the United States through MIMA-Pro for general soft-tissue microwave ablation.9
Strengths
- Large cited commercial position
- Recent evidence in very large nodules
- Broader interventional-oncology experience
- U.S.-cleared general soft-tissue platform
Limitations
- Less thyroid-specific global branding
- Fewer high-quality comparisons than Canyon
- Less visible thyroid training infrastructure
- No thyroid-specific U.S. indication identified
Other MWA platforms physicians should know
Biomedical / Terumo TATO
A dedicated European microwave platform with fine thyroid antennas and Terumo distribution across Europe, the Middle East and Africa. It remains important where European hospital procurement, service and clinical networks are decisive.10
HS AMICA
An established European multi-organ RF/MW platform with published thyroid use. It is relevant particularly where interventional-radiology programs prefer one broader oncology system rather than a thyroid-only commercial ecosystem.
Which MWA platform should a physician consider?
Select the priority that most closely reflects the program. The recommendation is a starting point—not a substitute for local mentorship, service and regulatory review.
Choose the primary procurement priority
Its named platform has the strongest thyroid-specific clinical evidence identified in this review. Confirm that the current generator and antenna configuration is supported by the evidence and available locally.
Practical comparison
| Platform | Best reason to consider it | Primary caution | Best fit |
|---|---|---|---|
| Canyon | Clinical evidence | Legacy evidence does not automatically validate every current configuration. | Evidence-led MWA program with experienced mentorship. |
| ECO | Scale + evidence | Local support and product continuity require verification. | High-volume center treating large or vascular nodules. |
| Baird | Thyroid support | Independent comparative evidence remains less developed. | Market where Baird training and service are strongest. |
| Vison | Large nodules | Less visible thyroid-specific international ecosystem. | Interventional-oncology center with large-nodule demand. |
The most evidence-supported generator is still the wrong purchase when the physician’s mentor, service network and consumable supply support a different platform.
What this ranking cannot establish
Worldwide procedure volume
No audited public registry identifies the number of thyroid procedures performed with each platform.
Intrinsic device superiority
Operator experience, case selection and technique can outweigh differences between technically capable systems.
Current-market continuity
Clinical evidence may involve older generators or antennas that differ from the products now being sold.
Is Canyon the true leader?
Yes—when the question is which manufacturer has the strongest identifiable device-specific clinical evidence in thyroid MWA.
That does not establish Canyon as the largest global supplier, the safest system for beginners or the best-supported platform in every country.
The most defensible final language is:
Canyon is the thyroid MWA clinical-evidence leader. ECO appears to lead commercial scale in the available China market data. Baird leads the cited China thyroid-specific commercial segment. Vison is a major underrecognized competitor.
MWA has matured into an established thyroid-ablation modality. But the manufacturer ranking remains secondary to the physician’s ultrasound skill, mentorship, case selection and ability to protect critical structures.
The true MWA leader for a particular patient is the platform used most competently by a physician who knows when MWA is—and is not—the correct treatment.
About the author
Philip James is a medical journalist and victim of unnecessary thyroid surgery. He founded RFAMD to expand informed access to nonsurgical thyroid treatment and to improve transparency around physician skill, technology and patient selection.
This report is not anti-surgery and does not recommend ablation for every patient. It argues for complete disclosure of reasonable options and treatment matched to the disease rather than the device a clinic happens to own.
How RFAMD assessed the market
RFAMD reviewed identifiable device-specific thyroid studies, official regulatory records, manufacturer product information and public company filings. The report separates four forms of leadership: clinical evidence, overall commercial scale, thyroid-specific commercialization and international visibility.
References
- Prospective randomized multicenter comparison of microwave and radiofrequency ablation for benign thyroid nodules. Radiology.
- Large cohort and long-term clinical literature involving the KY-2000 microwave platform. PubMed Central.
- Canyon Medical ThyTip thyroid microwave antenna information. Canyon Medical.
- FDA 510(k) summary K241827: Canyon KY-2000A/KY-2100A. U.S. Food and Drug Administration.
- Baird Medical annual report, including cited Frost & Sullivan China MWA market data. U.S. Securities and Exchange Commission.
- Comparison of STARMED RFA and ECO microwave ablation in predominantly solid benign thyroid nodules. European Radiology.
- FDA 510(k) K232240: Baird Medical BD-GT Microwave Ablation System. U.S. Food and Drug Administration.
- Microwave ablation of benign thyroid nodules measuring at least 4 cm using the Vison MTC-3C system. PubMed Central.
- FDA 510(k) K223272: SurBlate Microwave Ablation System. U.S. Food and Drug Administration.
- TATO microwave ablation platform. Terumo Europe.
Corrections: RFAMD welcomes documented factual corrections from physicians, researchers and manufacturers. Material corrections should be recorded in a dated revision history.